Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Neuropathy Clear all
Completed Phase 2 Interventional

A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV

NCT05005078
View directory record Official record
Conditions
HIV Associated Polyneuropathy
Interventions
WST-057, Placebo
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Palm Springs, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV

NCT00826345
View directory record Official record
Conditions
Peripheral Neuropathy, HIV, AIDS, HIV Infections
Interventions
Acupuncture/Moxibustion
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Not applicable Interventional

The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients

NCT00000817
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Amitriptyline hydrochloride, Amitriptyline hydrochloride placebo, Point acupuncture
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1997
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Phase 2 Interventional

A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy

NCT00000842
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Nerve Growth Factor, Recombinant Human
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
14
States / cities
Los Angeles, California • San Mateo, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Phase 2 Interventional

Acupuncture/Moxibustion for Peripheral Neuropathy in HIV

NCT00317291
View directory record Official record
Conditions
Peripheral Neuropathies, HIV Infections
Interventions
Acupuncture/Moxibustion, Sham acupuncture/Placebo moxibustion
Procedure · Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Phase 2 Interventional

A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection

NCT00000793
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Mexiletine hydrochloride, Benztropine mesylate, Amitriptyline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Phase 1Phase 2 Interventional

Painful HIV Neuropathy and Alpha-Lipoic Acid

NCT00079807
View directory record Official record
Conditions
HIV, Peripheral Neuropathy
Interventions
Alpha-Lipoic Acid
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Not applicable Interventional Results available

Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain

NCT03855111
View directory record Official record
Conditions
Neuropathic Pain, HIV Neuropathy, HIV/AIDS, Pain
Interventions
Standard Acupuncture / Moxibustion, Individualized (Tailored) Active Acupuncture / Moxibustion
Other
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 11, 2026, 12:14 AM EDT
Withdrawn Phase 2 Interventional

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

NCT00723918
View directory record Official record
Conditions
HIV-associated Neuropathy, Polyneuropathy
Interventions
SAB378, methadone, SAB placebo, Methadone placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
San Diego, California • Brooklyn, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Effects of TENS and Mindfulness Meditation in Persons With HIV-related Neuropathy

NCT04868123
View directory record Official record
Conditions
HIV Infections
Interventions
Transcutaneous Nerve Stimulation (TENS), Mindfulness Meditation
Device · Behavioral
Lead sponsor
Rutgers University
Other
Eligibility
18 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Blackwood, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Phase 3 Interventional

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

NCT00064623
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
35
States / cities
Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Jun 11, 2026, 12:14 AM EDT
Not listed Phase 2 Interventional

Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy

NCT00061152
View directory record Official record
Conditions
HIV Infections
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
West Hollywood, California • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 13, 2007 · Synced Jun 11, 2026, 12:14 AM EDT
Active, not recruiting Phase 2 Interventional

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

NCT06568042
View directory record Official record
Conditions
Neuropathic Pain, Distal Sensory Polyneuropathy
Interventions
LY3848575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Chandler, Arizona • Phoenix, Arizona • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

NCT00050271
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases
Interventions
Acetyl-L-carnitine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
10
States / cities
Palo Alto, California • Atlanta, Georgia • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Phase 1Phase 2 Interventional

Marijuana for HIV-Related Peripheral Neuropathy

NCT00046722
View directory record Official record
Conditions
Peripheral Nervous System Diseases, HIV Infections
Interventions
Smoked Marijuana
Drug
Lead sponsor
Center for Medicinal Cannabis Research
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2007 · Synced Jun 11, 2026, 12:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pain and Sensory Changes Assessment in HIV+ Patients

NCT00422695
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jun 11, 2026, 12:14 AM EDT
Terminated Phase 3 Interventional

Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy

NCT00085761
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Sarasota, Florida • Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Phase 1Phase 2 Interventional

Medicinal Cannabis for Painful HIV Neuropathy

NCT00255580
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Smoked cannabis
Drug
Lead sponsor
Center for Medicinal Cannabis Research
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2008 · Synced Jun 11, 2026, 12:14 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

NCT04353778
View directory record Official record
Conditions
HIV, Non-HIV, Vagus Nerve Dysfunction
Interventions
Pyridostigmine, Placebos, non-invasive vagal nerve stimulation
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 11, 2026, 12:14 AM EDT
Completed No phase listed Observational

Neuropathy Walks (Cross-sectional)

NCT04889521
View directory record Official record
Conditions
HIV Infections
Interventions
No intervention
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Blackwood, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jun 11, 2026, 12:14 AM EDT
Not listed Phase 2 Interventional

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

NCT01537705
View directory record Official record
Conditions
Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
Interventions
Neuron012703 (Medical Food)
Drug
Lead sponsor
Targeted Medical Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Jun 11, 2026, 12:14 AM EDT
Terminated Phase 3 Interventional Results available

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT01049217
View directory record Official record
Conditions
Neuropathy
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • North Hollywood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

NCT00232141
View directory record Official record
Conditions
HIV Infections, Peripheral Neuropathy
Interventions
pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jun 11, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS

NCT00002083
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Peptide T
Drug
Lead sponsor
Advanced Peptides
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 12:14 AM EDT